Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$118.5M-10.2%$132.01M-13.3%$152.18M-12.9%$174.71M-0.6%$175.71M+4.2%
$53M+37.3%$38.6M+20.9%$31.92M+12.6%$28.36M+10.0%$25.78M+8.2%
$171.5M+0.5%$170.6M-7.3%$184.09M-9.3%$203.07M+0.8%$201.49M+4.7%
-$171.5M-0.5%-$170.6M+7.3%-$184.09M+9.3%-$203.07M-0.8%-$201.49M-4.7%
$19.71M+23.6%$15.95M+25.4%$12.72M+3.4%$12.3M-5.2%$12.97M-11.1%
$19.72M+23.6%$15.95M+25.3%$12.73M+3.5%$12.29M-5.3%$12.98M-11.1%
-$151.78M+1.9%-$154.65M+9.8%-$171.36M+10.2%-$190.77M-1.2%-$188.51M-6.0%
-$2.00+13.8%-$2.32+21.4%-$2.95+17.1%-$3.56+4.6%-$3.73-2.5%
-$171.45M-0.5%-$170.55M+7.3%-$184.03M+9.3%-$203.01M-0.8%-$201.44M-4.7%
-$171.5M-0.5%-$170.6M+7.3%-$184.09M+9.3%-$203.07M-0.8%-$201.49M-4.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Mineralys Therapeutics, Inc.'s income statement data come from?
Every line is extracted from Mineralys Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.